K Pharma,Inc. (JP:4896)

:4896

4896

K Pharma,Inc.

RESEARCH TOOLSreports

K Pharma,Inc. (4896) Price & Analysis

0 Followers

4896 Stock Chart & Stats

¥651.00

¥14.00(2.16%)

At close: Jan 08 4:00 PM EST

¥651.00

¥14.00(2.16%)

Day’s Range― - ―

52-Week Range¥540.00 - ¥1,032.00

Previous CloseN/A

Volume10.50K

Average Volume (3M)48.08K

Market Cap

¥8.61B

Enterprise Value¥6.37B

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta1.01

Next Earnings

May 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-26.83

Shares Outstanding11,622,600

10 Day Avg. Volume47,520

30 Day Avg. Volume48,080

Financial Highlights & Ratios

PEG Ratio-0.44

Price to Book (P/B)6.05

Price to Sales (P/S)0.00

P/FCF Ratio-8.24

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Prior Revenue And Profitable Year (2023)The company reported revenue and net income in 2023 (¥1.0B revenue, ¥260M net income), demonstrating prior commercial or milestone capability. This historical revenue shows the business can generate cash and commercialize outputs, reducing pure pre-revenue execution risk over time and providing a precedent for potential revenue recovery if programs advance or partnerships occur.

Modest Improvement In Cash Burn (2025 Vs 2024)Operating and free cash flow trends improved modestly in 2025 versus 2024, indicating some reduction in cash outflows. A sustained decline in burn rate implies better cost discipline or program completion, extending runway and reducing near-term financing pressure if management maintains the trend across upcoming quarters.

Material Asset Base (~¥2.94B)Despite equity erosion, total assets of roughly ¥2.94B provide a tangible capital base. That asset stock offers strategic optionality—collateral for financing, monetizable assets, or bargaining power in partnerships—that can help fund R&D or bridge operations over a multi-month horizon without relying solely on immediate revenue generation.

Bears Say

Zero Revenue In 2024–2025The company reported zero revenue in 2024–2025 and shifted from profitable 2023 to large operating and net losses. Persistent absence of revenue removes margin generation and forces reliance on external financing or partnerships to fund development, raising execution risk and making medium-term sustainability contingent on successful funding or commercial milestones.

Sustained Negative Operating And Free Cash FlowOperating and free cash flow were negative (~-¥0.98B to -¥0.92B annually) in 2024–2025, indicating sustained cash burn. Continued annual outflows at this scale will deplete reserves quickly relative to the reduced equity base, increasing the probability of dilutive capital raises, curtailed R&D programs, or unfavorable financing terms in the medium term.

Rising Leverage And Eroding EquityEquity declined from ¥3.10B to ¥1.27B while total debt rose to ¥1.5B, pushing debt/equity to ~1.19x. This combination erodes financial flexibility, raises financing costs and solvency risk, and limits the company's ability to absorb shocks or secure attractive financing, which can constrain long-term development and strategic options.

4896 FAQ

What was K Pharma,Inc.’s price range in the past 12 months?

K Pharma,Inc. lowest stock price was ¥540.00 and its highest was ¥1032.00 in the past 12 months.

What is K Pharma,Inc.’s market cap?

K Pharma,Inc.’s market cap is ¥8.61B.

When is K Pharma,Inc.’s upcoming earnings report date?

K Pharma,Inc.’s upcoming earnings report date is May 20, 2026 which is in 42 days.

How were K Pharma,Inc.’s earnings last quarter?

K Pharma,Inc. released its earnings results on Feb 12, 2026. The company reported -¥26.83 earnings per share for the quarter, missing the consensus estimate of N/A by -¥26.83.

Is K Pharma,Inc. overvalued?

According to Wall Street analysts K Pharma,Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does K Pharma,Inc. pay dividends?

K Pharma,Inc. does not currently pay dividends.

What is K Pharma,Inc.’s EPS estimate?

K Pharma,Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does K Pharma,Inc. have?

K Pharma,Inc. has 11,622,600 shares outstanding.

What happened to K Pharma,Inc.’s price movement after its last earnings report?

K Pharma,Inc. reported an EPS of -¥26.83 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.422%.

Which hedge fund is a major shareholder of K Pharma,Inc.?

Currently, no hedge funds are holding shares in JP:4896

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

K Pharma,Inc.

K Pharma,Inc. engages in the research, development, manufacture, and sale of regenerative medicines and pharmaceutical products in Japan. It develops regenerative medicine products using disease-specific induced pluripotent stem (iPS) cell technology for spinal cord injuries and cerebral infarctions. The company was incorporated in 2016 and is based in Minato, Japan.